Received Oct 30, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| PPV | PNEUMO (PNEUMOVAX) | MERCK & CO. INC. | UNK | — | — |
Polysaccharide vaccine response while not on IgG replacement was only available for patient 5, and she had protective titers to 7 of 23 (30%) after Pneumovax-23 vaccination; Literature report. This literature marketed report has been received from the authors of a published article, titled as stated above, and refers to a 20-year-old female patient. The patient's medical history was not reported. The patient's concurrent conditions included common variable immunodeciency (CVID) (also reported as autosomal dominant activation-induced cytidine deaminase (AICDA) deciency). Concomitant therapies were not reported. On an unknown date, the patient was vaccinated with Pneumococcal Vaccine, Polyvalent (23-valent) (PNEUMOVAX 23) (dose, units, route of administration, indication, expiration date, and lot # were not reported). On an unknown date, Polysaccharide vaccine response (also reported as Streptococcal pneumoniae response) while not on IgG replacement was measured for the patient, and she had protective titers to 7 of 23 (30%) after the vaccination (Antibody test abnormal). At the reporting time, the outcome of the event was unknown. The event of Antibody test abnormal was considered to be related to Pneumococcal Vaccine, Polyvalent (23-valent) (PNEUMOVAX 23). A copy of the published article is attached as further documentation of the patient's experience. Lot# is being requested and will be submitted if received.
Common variable immunodeficiency
Test Name: Streptococcus pneumoniae antibody test; Result Unstructured Data: Polysaccharide vaccine response while not on IgG replacement: protective titers to 7 of 23 (30%)